Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer - Wikidata - wikimedia - TriplyDB

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

http://www.wikidata.org/entity/Q28376841

about

Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane Antiangiogenesis cocktails - stirred or shaken?PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity A review of Judah Folkman's remarkable achievements in biomedicine New chemotherapy strategies and biological agents in the treatment of childhood ependymoma Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?Recent translational research: computational studies of breast cancer Antiangiogenic gene therapy of cancer: recent developments Overexpression of beta1-chain-containing laminins in capillary basement membranes of human breast cancer and its metastases Polysaccharides from the root of Angelica sinensis protect bone marrow and gastrointestinal tissues against the cytotoxicity of cyclophosphamide in mice.Metronomic Chemotherapy for Metastatic Breast Cancer – a Systematic Review of the Literature Dose-Dense Chemotherapy in Metastatic Breast Cancer: Shortening the Time Interval for a Better Therapeutic Index Head and neck cancer: metronomic chemotherapy The Contribution of Angiogenesis to the Process of Metastasis Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status Broad targeting of angiogenesis for cancer prevention and therapy Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer Metronomic Chemotherapy--A New Path to Treat Advanced Non-small Cell Lung Cancer Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance Future paradigms for precision oncology Review of Cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments The war on cancer: a military perspective Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI A new antiproliferative noscapine analogue: chemical synthesis and biological evaluation Tumor angiogenesis Reversible p53 inhibition prevents cisplatin ototoxicity without blocking chemotherapeutic efficacy Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.Normalization of the vasculature for treatment of cancer and other diseases.Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis.Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.Rapid induction of orthotopic hepatocellular carcinoma in immune-competent rats by non-invasive ultrasound-guided cells implantation.Selected current data on metronomic therapy (and its promise) from India Heterogeneous vascular dependence of tumor cell populations Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

P2860

Q24314623-284CA3BA-87FF-4E56-B587-AAEE79F4F388 Q24548357-4B431311-51CC-4C63-9110-F4D8F47EFC62 Q24553314-988A1471-DD19-4605-AEB2-37D10EC692E3 Q24561642-FD4D9274-B23B-4602-A465-633ACFC6FD34 Q24652770-B736C4A4-F1DC-46F6-AB4B-1AB947EF1828 Q24658324-C5D91471-EB2F-4687-8086-EF2CBE91FFC4 Q24676378-F78E2BB7-22AE-41C0-840B-444BB51E509E Q24794969-BCCB65B8-7BBE-4B6A-B351-B3C118D313DD Q24797101-B4973C5B-4F31-4ABD-8A9A-8AB6B87FDDB6 Q24803786-07A5E6CA-3B07-4441-91C5-DD38BA5D994A Q24810498-45CB46D5-EF5F-42C1-81B9-2BCB77013E28 Q25256110-89AF77AC-2F31-4C13-AA4B-9E1ADD85E6E8 Q26745462-55591F76-7DDC-4AEB-BA44-FF45A3874721 Q26751245-728345DC-D781-4839-B5F0-50854EC92CC1 Q26784018-95FA999E-2C12-457B-B968-40CDC1B130AC Q26801841-A49AFFDF-C28D-4E9A-A07C-3622E0F81C54 Q27001560-5B8AFB2F-7378-4B7C-8D3A-FE3213096672 Q27002903-046D5C7E-4B52-42F8-8B43-3B0D69760ADE Q27011840-010FF658-B14F-4247-B059-7B3E175627B7 Q27015786-F463FA66-3B6B-4498-9FA2-D7B87C4F6974 Q27023579-2C6E7257-AFFA-4A9F-A31B-F75FAF1CC823 Q28078745-1A439642-481F-4F77-90C3-E202C0713015 Q28082382-B9586BF1-A684-48FC-9851-A5D5F98A8AAA Q28083060-5304B1F2-F13E-473C-9854-0F4348018720 Q28253120-7B877578-F084-47BB-AFE3-E3A34C8E69AF Q28540575-1FEF8E04-936C-434A-A9AF-21D1B5ED9A08 Q28818249-C9A5942C-95D2-4F8F-BC0F-7265DB0F8654 Q29614938-301368A0-EE05-4004-904A-CD0CC8F36089 Q30366115-FC9735D8-C903-4AA3-B9BA-7AA8BA2726E4 Q30438696-D14F7C9D-55FE-4ECC-A4DC-F515DC284CB7 Q30441458-1999C784-20A0-4C80-A40C-1592B32D1F91 Q30455612-9267FF58-58E7-4331-A917-365E7C690846 Q30469815-7C21A5C1-3B52-482B-AA7B-CF5A2E825BAF Q30471456-674EDD87-2CD1-4445-885C-A5A81604B87D Q30523830-843EEB65-439C-49AC-A408-EF4F8E4AEDF6 Q30846827-D60783A8-3463-4017-8E60-59980BE65443 Q30986337-F29301B5-1C7F-4296-B3E1-AB49E4DF6B06 Q31106477-B8AE77C3-F91A-43BD-BEEF-4B81D8D79D9C Q33181864-8649A851-3C2E-499C-A4E4-C16A5E013427 Q33187344-E8997030-A9B3-4C2A-9161-A9B61A2C85E9

P2860

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

http://www.wikidata.org/entity/Q28376841

description

2000 nî lūn-bûn

@nan

2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Antiangiogenic scheduling of c ...... rimental drug-resistant cancer

@ast

Antiangiogenic scheduling of c ...... rimental drug-resistant cancer

@en

Antiangiogenic scheduling of c ...... rimental drug-resistant cancer

@nl

type

label

Antiangiogenic scheduling of c ...... rimental drug-resistant cancer

@ast

Antiangiogenic scheduling of c ...... rimental drug-resistant cancer

@en

Antiangiogenic scheduling of c ...... rimental drug-resistant cancer

@nl

prefLabel

Antiangiogenic scheduling of c ...... rimental drug-resistant cancer

@ast

Antiangiogenic scheduling of c ...... rimental drug-resistant cancer

@en

Antiangiogenic scheduling of c ...... rimental drug-resistant cancer

@nl

P1433

Q28376841-A59C7368-5C08-4C21-8F13-67CB302D6E6A

P1476

Q28376841-E1E59E04-5AEA-424E-BE92-3EAF2259AE8C

P2093

Q28376841-17A252E1-4D84-4329-9DB9-7CB9116DB545

Q28376841-28A845F8-EBCF-4290-9DC7-51E3C6C74D43

Q28376841-5BE40CAA-C65C-4399-8766-D291458C9FF8

Q28376841-807FBC44-CC2E-44F0-906F-3AFA0A7CB51A

Q28376841-85340412-904F-498C-9BDA-4099A495F534

Q28376841-B27DF5F2-624B-4C92-B436-1A672ADBB2EB

Q28376841-D6BFA98B-A5F9-4893-809D-C9BA31A2E3C7

P304

Q28376841-7F204274-31CF-4570-AA3D-C10FF665EA16

P31

Q28376841-DE87F714-E84A-4DD3-B939-170BD195AC42

P3181

Q28376841-82CF8EC4-2245-4FB0-B303-E9548563C10A

P407

Q28376841-872B0BD0-B5A7-499D-85B3-6C3A64A5F06F

P433

Q28376841-9E4B7C93-B87F-4D2E-A9CD-F317D66D5D23

P478

Q28376841-FFE11DB6-84CD-4A4D-A3A6-7CFCF854BF18

P577

Q28376841-C6C312E0-2AB3-45A0-BAFC-4A20477A271F

P698

Q28376841-513AF41B-E60E-44F5-9570-A0808EA8A207

P921

Q28376841-E2A40621-342E-4FDD-82B6-D4D958537302

P3181

P1433

Cancer Research

P1476

Antiangiogenic scheduling of c ...... rimental drug-resistant cancer

@en

P2093

B M Kräling

http://www.w3.org/2001/XMLSchema#string

B Marshall

http://www.w3.org/2001/XMLSchema#string

B Shi

http://www.w3.org/2001/XMLSchema#string

C E Butterfield

http://www.w3.org/2001/XMLSchema#string

J Folkman

http://www.w3.org/2001/XMLSchema#string

M S O'Reilly

http://www.w3.org/2001/XMLSchema#string

T Browder

http://www.w3.org/2001/XMLSchema#string

P304

1878-86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2528015

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2000-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10766175

http://www.w3.org/2001/XMLSchema#string

P921